Ann: 30 June 20 Preliminary Update, page-4

Cash at $6.5m and taking out the $0.4m addition of debt, then FCF for the half was ~$2.8m. Which is a great result, revenues may be down but costs are down even more. It'll be grind waiting for hospitals/research centers to start investing in software/equipment again, but so be it.

I'm just hoping the team didn't cut back on R&D expenditure to achieve the positive cashflow result for the half !!! I'd rather be hit with a cap raising than to fall behind the competition in med related tech.

The intangibles were sitting at $9.7m, part of that looks like will be written off in the full year accounts.